Minocycline, for example, was able to slow disease in SOD1(G37R) mice (Kriz et al., 2002) but was shown to accelerate disease in human clinical trials involving a diverse ALS patient group (Gordon et al., 2007). Here, SOD1 is linked to amyotrophic lateral sclerosis.